At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 8 enrolled
Drug / intervention
Imsidolimabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Arm Multiple Dose Study to Assess the Efficacy and Safety of ANB019 in Subjects With Generalized Pustular Psoriasis
In Brief
A Phase 2 clinical trial evaluating Imsidolimab for Generalized Pustular Psoriasis. Completed, enrolled 8 participants across 13 sites in 4 countries.
Detailed Summary
The main objectives of this study are to evaluate the efficacy, safety and tolerability of imsidolimab in adults with active GPP.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGeneralized Pustular Psoriasis
CountriesPoland, South Korea, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedAug 2018
Enrollment StartJan 2019
Primary CompletionJan 2021
TodayJul 2026
First PostedAug 8, 2018
Enrollment StartJan 30, 2019
Primary CompletionJan 20, 2021
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 7.9 years ago
Interventions
Imsidolimabbiological
Humanized monoclonal antibody